Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
Instituto de Salud Carlos III (CB06/06/1088)
Instituto de Salud Carlos III (PI16/00049)
Instituto de Salud Carlos III (PI19/0141)
Canadian Institutes of Health Research (137772)
Canadian Institutes of Health Research (FDN143285)
Canadian Institutes of Health Research (OV3-170344)
European Regional Development Fund (FEDER)
Fundación Científica Asociación Española Contra el Cáncer
- License Information
-
More Information
Article History
Received: 28 September 2020
Accepted: 30 September 2020
First Online: 12 October 2020
Compliance with ethical interest
:
: ASS reports consulting fees from Apeiron Biologics, Baxter, and Xenios. JV received grant support from Maquet. UT declares no competing interests.
Free to read: This content has been made available to all.
